Physician profile
Malcolm Dulock
NPI 1922198647
$289.49
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.55 · 2020: $99.56 · 2021: $82.76 · 2022: $48.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $191.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2020 | |
| Amgen INC. | $15.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Dulock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.